esomeprazol sun 40 mg pulver zur herstellung einer injektions- /infusionslösung
sun pharmaceuticals germany gmbh (8127792) - esomeprazol-natrium - pulver zur herstellung einer injektions-/infusionslösung - teil 1 - pulver zur herstellung einer injektions-/infusionslösung; esomeprazol-natrium (33228) 42,5 milligramm
esomeprazol sun 40 mg pulver zur herstellung einer injektions- bzw. infusionslösung
sun pharmaceuticals germany gmbh (8127792) - esomeprazol-natrium - pulver zur herstellung einer injektions- bzw. infusionslösung - teil 1 - pulver zur herstellung einer injektions- bzw. infusionslösung; esomeprazol-natrium (33228) 42,6 milligramm
esomeprazol-elpen 40 mg magensaftresistente tabletten
elpen pharmaceutical co. inc. beiname: elpen, elpen s.a., elpen a.e. (8066783) - esomeprazol-hemimagnesium 1 h<2>o - magensaftresistente tablette - teil 1 - magensaftresistente tablette; esomeprazol-hemimagnesium 1 h<2>o (37195) 43,38 milligramm
esomeprazol-elpen 20 mg magensaftresistente tabletten
elpen pharmaceutical co. inc. beiname: elpen, elpen s.a., elpen a.e. (8066783) - esomeprazol-hemimagnesium 1 h<2>o - magensaftresistente tablette - teil 1 - magensaftresistente tablette; esomeprazol-hemimagnesium 1 h<2>o (37195) 21,69 milligramm
esomeprazol-elpen 40 mg pulver zur herstellung einer injektions- bzw. infusionslösung
elpen pharmaceutical co. inc. beiname: elpen, elpen s.a., elpen a.e. (8066783) - esomeprazol-natrium - pulver zur herstellung einer injektions- /infusionslösung - teil 1 - pulver zur herstellung einer injektions- /infusionslösung; esomeprazol-natrium (33228) 42,6 milligramm
sativex 27 mg/25 mg spray zur anwendung in der mundhöhle
jazz pharmaceuticals ireland limited - geschäftsanschrift - (8176856) - 38-44 mg dickextrakt aus cannabis sativa l., folium cum flore thc-chemotyp (cannabisblätter und -blüte) entsprechend 27 mg delta-9-tetrahydrocannabinol (thc), auszugsmittel: flüssiges kohlendioxid; 35-42 mg dickextrakt aus cannabis sativa l., folium cum flore cbc-chemotyp (cannabisblätter und -blüte) entsprechend 25 mg cannabidiol (cbd), auszugsmittel: flüssiges kohlendioxid - spray zur anwendung in der mundhöhle - 38-44 mg dickextrakt aus cannabis sativa l., folium cum flore thc-chemotyp (cannabisblätter und -blüte) entsprechend 27 mg delta-9-tetrahydrocannabinol (thc), auszugsmittel: flüssiges kohlendioxid (90001) 38 milligramm; 35-42 mg dickextrakt aus cannabis sativa l., folium cum flore cbc-chemotyp (cannabisblätter und -blüte) entsprechend 25 mg cannabidiol (cbd), auszugsmittel: flüssiges kohlendioxid (90002) 35 milligramm
clopidogrel-splendris 75 mg filmtabletten
splendris pharmaceuticals gmbh - geschäftsanschrift - (8141473) - clopidogrelhydrogensulfat - filmtablette - teil 1 - filmtablette; clopidogrelhydrogensulfat (29200) 97,86 milligramm
lvabradin sandoz 5 mg filmtabletten
sandoz pharmaceuticals ag - ivabradinum - filmtabletten - ivabradinum 5 mg zu ivabradini oxalas, antiox.: e 321, excipiens pro compresso dunst. - symptomatische behandlung der chronischen stabilen angina pectoris; behandlung der chronischen herzinsuffizienz - synthetika
lvabradin sandoz 7.5 mg filmtabletten
sandoz pharmaceuticals ag - ivabradinum - filmtabletten - ivabradinum 7,5 mg zu ivabradini oxalas, antiox.: e 321, excipiens pro compresso dunst. - symptomatische behandlung der chronischen stabilen angina pectoris; behandlung der chronischen herzinsuffizienz - synthetika
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastische mittel - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie ist indiziert für die behandlung von erwachsenen patienten mit lokal fortgeschrittenem oder metastasiertem nsclc nach vorheriger chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie ist indiziert für die behandlung von erwachsenen patienten mit lokal fortgeschrittenem oder metastasiertem nsclc nach vorheriger chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.